长江商报消息 ●长江商报记者 徐佳 国邦医药（605507.SH）引入地方国资。 8月20日晚间，国邦医药披露股东权益变动，公司3名股东拟通过协议转让的方式，作价7.91亿元向浙江省国有资 本运营有限公司（以下简称"国有运营公司"）转让所持国邦医药3830.63万股，占公司总股本的6.85%。 长江商报记者注意到，国有运营公司由浙江省国资委100%持股，是多家A股上市公司的重要股东。本次交易完成 之后，国有运营公司将成为国邦医药第四大股东。 国邦医药表示，本次协议转让系转让方基于自身规划安排以及支持上市公司优化股权结构、引入认可公司价值和 看好未来发展的战略投资者、推动上市公司战略发展。未来，国有运营公司拟支持公司在医药领域的全面发展， 协同公司进一步做大做强，提升公司抗风险能力。 作为一家小分子生命健康活性化合物的平台型企业集团，国邦医药竞争优势突出，公司近20个产品的市场占有率 名列前茅。 随着核心产品竞争力和市场占有率提升，2025年上半年，国邦医药实现营业收入30.26亿元，同比增长4.63%；归 属于上市公司股东的净利润（净利润，下同）4.56亿元，同比增长12.6%。 数据显示，自2021年上市以 ...

Core Viewpoint - Guobang Pharmaceutical's performance in the first half of 2025 reflects growth driven by core business deepening, continuous R&D investment, and collaborative efforts in upgrading the industrial chain [2] Financial Performance - In the first half of 2025, Guobang Pharmaceutical achieved operating revenue of 3.026 billion yuan, a year-on-year increase of 4.63% - The net profit attributable to shareholders reached 456 million yuan, representing a year-on-year growth of 12.60% [1] Business Segments - The company maintains a leading position in pharmaceutical raw materials, with significant achievements in animal health, plant protection, and food-drug homologation sectors [1] - The animal health business has seen a notable decrease in marginal costs due to scale advantages, with over 2,000 tons of florfenicol shipped and a growing market share [1] - The plant protection project has successfully entered trial production, and the Seven Fang Cup series health drinks have been launched in the market [1] Market Expansion and Global Strategy - Guobang Pharmaceutical's products are distributed across 117 countries and regions on six continents, with over 5,000 supply partners [2] - The company actively participated in 18 domestic and international exhibitions, including API and CPHI, to expand its global market channels [2] - The proportion of products certified by international authorities continues to rise, with 18 products having obtained CEP certification and 7 products approved by the FDA [2] Cash Flow and Operational Quality - The net cash flow from operating activities turned positive to 103 million yuan, indicating a significant improvement in the company's operational quality [2] - The robust cash flow situation supports ongoing R&D investments, new product pipeline advancements, and capacity expansion [2] R&D and Certification - The company is increasing its investment in R&D and production management, aiming to expand the coverage of international certifications such as CEP and FDA [3]